Persistent inflammation during anti-tuberculosis treatment with diabetes comorbidity

  1. Nathella Pavan Kumar
  2. Kiyoshi F Fukutani
  3. Basavaradhya S Shruthi
  4. Thabata Alves
  5. Paulo S Silveira-Mattos
  6. Michael S Rocha
  7. Kim West
  8. Mohan Natarajan
  9. Vijay Viswanathan
  10. Subash Babu
  11. Bruno B Andrade
  12. Hardy Kornfeld  Is a corresponding author
  1. National Institutes of Health, India
  2. Fundação José Silveira, Brazil
  3. Prof M Viswanathan Diabetes Research Center, India
  4. University of Massachusetts Medical School, United States
  5. National Institute for Research in Tuberculosis, India

Abstract

Diabetes mellitus (DM) increases risk for pulmonary tuberculosis (TB) and adverse treatment outcomes. Systemic hyper-inflammation is characteristic in people with TB and concurrent DM (TBDM) at baseline, but the impact of TB treatment on this pattern has not been determined. We measured 17 plasma cytokines and growth factors in longitudinal cohorts of Indian and Brazilian pulmonary TB patients with or without DM. Principal component analysis revealed virtually complete separation of TBDM from TB individuals in both cohorts at baseline, with hyper-inflammation in TBDM that continued through treatment completion at six months. By one year after treatment completion, there was substantial convergence of mediator levels between groups within the India cohort. Non-resolving systemic inflammation in TBDM comorbidity could reflect delayed lesion sterilization or non-resolving sterile inflammation. Either mechanism portends unfavorable long-term outcomes including risk for recurrent TB and for damaging immune pathology.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1 through 5.

Article and author information

Author details

  1. Nathella Pavan Kumar

    International Center for Excellence in Research, National Institutes of Health, Chennai, India
    Competing interests
    The authors declare that no competing interests exist.
  2. Kiyoshi F Fukutani

    Multinational Organization Network Sponsoring Translational and Epidemiological Research, Fundação José Silveira, Salvador, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  3. Basavaradhya S Shruthi

    Prof M Viswanathan Diabetes Research Center, Chennai, India
    Competing interests
    The authors declare that no competing interests exist.
  4. Thabata Alves

    Multinational Organization Network Sponsoring Translational and Epidemiological Research, Fundação José Silveira, Salvador, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  5. Paulo S Silveira-Mattos

    Multinational Organization Network Sponsoring Translational and Epidemiological Research, Fundação José Silveira, Salvador, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  6. Michael S Rocha

    Multinational Organization Network Sponsoring Translational and Epidemiological Research, Fundação José Silveira, Salvador, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  7. Kim West

    University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5744-0280
  8. Mohan Natarajan

    National Institute for Research in Tuberculosis, Chennai, India
    Competing interests
    The authors declare that no competing interests exist.
  9. Vijay Viswanathan

    Prof M Viswanathan Diabetes Research Center, Chennai, India
    Competing interests
    The authors declare that no competing interests exist.
  10. Subash Babu

    International Center for Excellence in Research, National Institutes of Health, Chennai, India
    Competing interests
    The authors declare that no competing interests exist.
  11. Bruno B Andrade

    Multinational Organization Network Sponsoring Translational and Epidemiological Research, Fundação José Silveira, Salvador, Brazil
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6833-3811
  12. Hardy Kornfeld

    University of Massachusetts Medical School, Worcester, United States
    For correspondence
    Hardy.Kornfeld@umassmed.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8970-7306

Funding

CRDF Global (USB1-31149-XX-13)

  • Hardy Kornfeld

CRDF Global (USB1-31149-XX-13)

  • Vijay Viswanathan

National Institutes of Health (U01AI115940)

  • Bruno B Andrade

Conselho Nacional de Desenvolvimento Científico e Tecnológico

  • Kiyoshi F Fukutani

Conselho Nacional de Desenvolvimento Científico e Tecnológico

  • Thabata Alves

Fundação de Amparo à Pesquisa do Estado da Bahia

  • Paulo S Silveira-Mattos

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

  • Kiyoshi F Fukutani

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

  • Bruno B Andrade

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: All research presented here was conducted according to the principles expressed in the Declaration of Helsinki. The Indian cohort study was approved by the Ethics Committee of the Prof. M. Viswanathan Diabetes Research Centre (ECR/51/INST/TN/2013/MVDRC/01). The Brazilian cohort study was approved by the Ethics Committee of the Maternidade Climério de Oliveira, Federal University of Bahia (CAAE: 0115.0.054.000-09). Written informed consent was obtained from all participants at both sites.

Copyright

© 2019, Kumar et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,566
    views
  • 378
    downloads
  • 42
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Nathella Pavan Kumar
  2. Kiyoshi F Fukutani
  3. Basavaradhya S Shruthi
  4. Thabata Alves
  5. Paulo S Silveira-Mattos
  6. Michael S Rocha
  7. Kim West
  8. Mohan Natarajan
  9. Vijay Viswanathan
  10. Subash Babu
  11. Bruno B Andrade
  12. Hardy Kornfeld
(2019)
Persistent inflammation during anti-tuberculosis treatment with diabetes comorbidity
eLife 8:e46477.
https://doi.org/10.7554/eLife.46477

Share this article

https://doi.org/10.7554/eLife.46477

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Armando Montoya-Garcia, Idaira M Guerrero-Fonseca ... Michael Schnoor
    Research Article

    Arpin was discovered as an inhibitor of the Arp2/3 complex localized at the lamellipodial tip of fibroblasts, where it regulated migration steering. Recently, we showed that arpin stabilizes the epithelial barrier in an Arp2/3-dependent manner. However, the expression and functions of arpin in endothelial cells (EC) have not yet been described. Arpin mRNA and protein are expressed in EC and downregulated by pro-inflammatory cytokines. Arpin depletion in Human Umbilical Vein Endothelial Cells causes the formation of actomyosin stress fibers leading to increased permeability in an Arp2/3-independent manner. Instead, inhibitors of ROCK1 and ZIPK, kinases involved in the generation of stress fibers, normalize the loss-of-arpin effects on actin filaments and permeability. Arpin-deficient mice are viable but show a characteristic vascular phenotype in the lung including edema, microhemorrhage, and vascular congestion, increased F-actin levels, and vascular permeability. Our data show that, apart from being an Arp2/3 inhibitor, arpin is also a regulator of actomyosin contractility and endothelial barrier integrity.

    1. Immunology and Inflammation
    Alexandra a Aybar-Torres, Lennon A Saldarriaga ... Lei Jin
    Research Article

    The significance of STING1 gene in tissue inflammation and cancer immunotherapy has been increasingly recognized. Intriguingly, common human STING1 alleles R71H-G230A-R293Q (HAQ) and G230A-R293Q (AQ) are carried by ~60% of East Asians and ~40% of Africans, respectively. Here, we examine the modulatory effects of HAQ, AQ alleles on STING-associated vasculopathy with onset in infancy (SAVI), an autosomal dominant, fatal inflammatory disease caused by gain-of-function human STING1 mutations. CD4 T cellpenia is evident in SAVI patients and mouse models. Using Sting1 knock-in mice expressing common human STING1 alleles HAQ, AQ, and Q293, we found that HAQ, AQ, and Q293 splenocytes resist STING1-mediated cell death ex vivo, establishing a critical role of STING1 residue 293 in cell death. The HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice did not have CD4 T cellpenia. The HAQ/SAVI(N153S), AQ/SAVI(N153S) mice have more (~10-fold, ~20-fold, respectively) T-regs than WT/SAVI(N153S) mice. Remarkably, while they have comparable TBK1, IRF3, and NFκB activation as the WT/SAVI, the AQ/SAVI mice have no tissue inflammation, regular body weight, and normal lifespan. We propose that STING1 activation promotes tissue inflammation by depleting T-regs cells in vivo. Billions of modern humans have the dominant HAQ, AQ alleles. STING1 research and STING1-targeting immunotherapy should consider STING1 heterogeneity in humans.